Merck & Co., Inc: Melanoma trials
The registry lists 42 Melanoma studies with Merck & Co., Inc as lead sponsor. 1 are open to participants now and 28 have results posted.
Phase 1 22Phase 2 17Phase 3 9Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)RecruitingNCT02332668Phase 1/2
- A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)Active, not recruitingNCT06099782Phase 2Results posted
- A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)TerminatedNCT05665595Phase 3Results posted
- Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyCompletedNCT04889118Phase 3Results posted
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)CompletedNCT04305041Phase 1/2Results posted
- Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)CompletedNCT04303169Phase 1/2Results posted
- Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)TerminatedNCT04152863Phase 2Results posted
- Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)CompletedNCT03820986Phase 3Results posted
- Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)CompletedNCT03715205Phase 4Results posted
- Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555)CompletedNCT03665597Phase 1Results posted
- Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)Active, not recruitingNCT03553836Phase 3Results posted
- SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)TerminatedNCT03552549Phase 2/3Results posted
- Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)TerminatedNCT03407170Phase 2Results posted
- Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)CompletedNCT02821000Phase 1Results posted
- Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)Active, not recruitingNCT02362594Phase 3Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)CompletedNCT02180061Phase 1Results posted
- A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)CompletedNCT02155322Phase 2Results posted
- A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)CompletedNCT02130466Phase 1/2Results posted
- Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)CompletedNCT02089685Phase 1/2Results posted
- Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)CompletedNCT01866319Phase 3Results posted
- Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)CompletedNCT01704287Phase 2Results posted
- A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)TerminatedNCT01636960Phase 1Results posted
- Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)CompletedNCT01295827Phase 1Results posted
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) ProtocolsCompletedNCT01178411Phase 1/2Results posted
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)CompletedNCT00753415Phase 1Results posted
- Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)CompletedNCT00749684Results posted
- Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)CompletedNCT00723710Results posted
- High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)CompletedNCT00457418Phase 1Results posted
- Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)CompletedNCT00091572Phase 3Results posted
- A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)Active, not recruitingNCT06961006Phase 2
- A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)CompletedNCT06894771Phase 1
- A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)Active, not recruitingNCT05933577Phase 3
- Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)CompletedNCT04700072Phase 1/2
- Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedNCT04305054Phase 1/2
- CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnNCT04060407Phase 1/2
- Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1TerminatedNCT02387125Phase 1
- Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1CompletedNCT02122861Phase 1
- Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)No longer availableNCT02083484
- A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic CancerCompletedNCT02015416Phase 1
- Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)CompletedNCT01294735Phase 1
- Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064)CompletedNCT00831545Phase 2
- Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid TumorsCompletedNCT00827177Phase 1